Celltrion Secures First Approval for Prolia Biosimilar in Korea
Celltrion has received its first approval for a biosimilar of Prolia (denosumab), a treatment for osteoporosis.
On the 22nd, Celltrion announced that it obtained simultaneous approvals from the…